Premium
Intra‐lesional interleukin‐2 therapy for in transit melanoma
Author(s) -
TempleOberle Claire F.,
Byers Brett A.,
Hurdle Valerie,
Fyfe Allison,
McKin J.Gregory
Publication year - 2014
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.23556
Subject(s) - medicine , tolerability , melanoma , lesion , disease , oncology , surgery , complete response , dermatology , adverse effect , chemotherapy , cancer research
Intra‐lesional interleukin‐2 (IL‐2) is effective in treating in transit melanoma metastases. Results from multiple studies were examined to evaluate the efficacy of IL‐2 for in transit disease. In the published literature, complete response ranged from 0% to 69% per patient, and 41% to 96% per lesion, with excellent tolerability. Combining the results of six studies show complete response in 50% of patients and 78% of lesions. Intra‐lesional IL‐2 should be considered early in the course of treatment for in transit disease, ahead of other, more toxic therapies. J. Surg. Oncol. 2014 109:327–331 . © 2014 Wiley Periodicals, Inc.